The Peptide Reference
The Peptide Reference
References
Reference/Fixed-ratio peptide combination

Glow Protocol

Multi-Peptide Skin Rejuvenation Complex

Human clinical
research use only

Combination featuring BPC-157, TB-500, and GHK-Cu marketed for skin rejuvenation and anti-aging. Individual components have research support, but combination protocols require careful dosing to avoid exceeding therapeutic ranges.

Single injection delivers multiple regenerative peptidesTheoretical additive effects from combined componentsConvenience factor versus individual peptide administration
01

Overview

Combination featuring BPC-157, TB-500, and GHK-Cu marketed for skin rejuvenation and anti-aging. Individual components have research support, but combination protocols require careful dosing to avoid exceeding therapeutic ranges.

BPC-157 provides anti-inflammatory effects; TB-500 supports angiogenesis; GHK-Cu stimulates collagen production. Fixed-ratio combinations may deliver individual peptides outside optimal therapeutic ranges.

Evidence profilederived from 3 references
A
Human clinical
Strongest design among the references on this page. Grade and effect size are separate facts and are never merged into one score.
02

Research indications

What the compound has been studied for, grouped by body system. Effect size is the reported magnitude where it was measured — not a recommendation.

Primary Applications3
Skin Rejuvenation

Theoretical synergistic effects; formal combination studies are limited

Large
Wound Healing

BPC-157 and TB-500 components support tissue regeneration

Moderate
Anti-Aging

GHK-Cu stimulates collagen production

Moderate
i

A large effect in a weak study and a small effect in a strong one are different things. Effect size is never evidence of use in people.

Quick factsreference only
Class
Fixed-ratio peptide combination
Typical dose
Per formulation instructions (typically 50mg GHK-Cu, 10mg TB-500, 10mg BPC-157 per dose)
Frequency
Once daily
Cycle length
8-12 weeks
Storage
Lyophilized: 2-8°C refrigerated; Reconstituted: 2-8°C refrigerated immediately after mixing
03

Molecular data

Type
Fixed-ratio peptide combination
04

Dosing reference

Doses reported in the literature and by suppliers. These are a record of what has been used in research — reference, never instruction.

ContextRouteAmountFrequency
Standard protocolSubcutaneousPer formulation instructionsOnce daily
05

Interactions

NAD+

Different mechanisms may complement cellular energy support

compatible
Vitamin C

Antioxidant support compatible with peptide effects

compatible
Retinoids

May increase skin sensitivity; monitor for irritation

monitor
Individual GHK-Cu

Risk of copper overdose when combining products

avoid
Individual BPC-157

Total daily intake may exceed therapeutic ranges

monitor
06

Quality checklist

  • Clear solution without particles
  • Proper packaging stating individual peptide amounts
  • !Verify peptide content matches supplier specifications
  • !Calculate individual peptide doses before starting
  • ×Excessive individual peptide amounts exceeding recommended ranges
  • ×Cloudy or discolored solution
07

What to expect

Week 1-2Initial tissue healing response begins
Week 2-4Visible skin improvements may begin
Week 4-8Collagen synthesis and regeneration effects
Week 8-12Peak effects; optimal skin rejuvenation
08

Safety

Commonly reported2
  • Injection site reactions
  • Temporary blue-green discoloration (from GHK-Cu)
Stop and seek advice3
  • Severe injection site reactions or infection
  • Allergic reactions (rash, difficulty breathing)
  • Signs of copper toxicity (nausea, jaundice)
09

FAQ

Is the Glow Protocol a proven combination or experimental?

The Glow Protocol is marketed as a skin rejuvenation combination but lacks peer-reviewed studies examining the three-peptide blend together. All evidence is extrapolated from individual BPC-157, TB-500, and GHK-Cu research. It remains experimental and theoretical rather than clinically validated as a combination.

What's the risk of combining three peptides in one product?

Fixed-ratio blends may deliver individual peptides outside optimal therapeutic ranges. For example, if the blend contains 5mg GHK-Cu but you only need 1-3mg injectable dose, you're overdosing on copper. Separate peptides allow dose customization, while combinations sacrifice flexibility for convenience.

Should I use Glow Protocol or buy individual BPC-157, TB-500, and GHK-Cu separately?

Individual peptides offer superior flexibility—you can adjust doses independently based on tolerance and response. The combination is convenient for those certain of equal benefits from all three, but if one component causes side effects, you're stuck. For serious users, separate purchases allow scientific optimization.

How long does Glow Protocol take to show visible skin improvements?

Timeline typically follows individual peptide timelines: healing response week 1-2, visible skin improvements by weeks 2-4, noticeable collagen effects by weeks 4-8, and peak rejuvenation effects by weeks 8-12. Results vary individually based on peptide quality, dosing accuracy, and baseline skin condition.

10

References

  1. 1
    Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth
    Staresinic, M., et al. · Journal of Orthopaedic Research · 2003

    Superior tendon healing with improved biomechanical properties (increased load of failure and Young's modulus), enhanced tendon-to-bone integration, and stimulated tendocyte growth in rat models.

  2. 2
    Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data
    Pickart, L., Margolina, A. · International Journal of Molecular Sciences · 2018

    Broad regenerative potential demonstrated across skin, lung, bone, liver, and stomach tissue; cell protective actions including anti-cancer, anti-inflammatory, DNA repair, and proteasome activation via gene modulation.

  3. 3
    A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers
    Wang X, Liu L, Qi L, et al. · Journal of Cellular and Molecular Medicine · 2021

    Phase I trial in 54 healthy subjects demonstrated recombinant thymosin β4 was well tolerated and safe across ascending IV doses up to 25 μg/kg with no significant accumulation.

For research use only. Nothing on this page is medical advice, and no number here is a recommendation to dose.